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Abstract
Background: Increasing evidence has revealed important roles for complex glycans as mediators of normal and
pathological processes. Glycosaminoglycans are a class of glycans that bind and regulate the function of a wide array of
proteins at the cell-extracellular matrix interface. The specific sequence and chemical organization of these polymers likely
define function; however, identification of the structure-function relationships of glycosaminoglycans has been met with
challenges associated with the unique level of complexity and the nontemplate-driven biosynthesis of these biopolymers.
Methodology/Principal Findings: To address these challenges, we have devised a computational approach to predict fine
structure and patterns of domain organization of the specific glycosaminoglycan, heparan sulfate (HS). Using chemical
composition data obtained after complete and partial digestion of mixtures of HS chains with specific degradative enzymes,
the computational analysis produces populations of theoretical HS chains with structures that meet both biosynthesis and
enzyme degradation rules. The model performs these operations through a modular format consisting of input/output
sections and three routines called chainmaker, chainbreaker, and chainsorter. We applied this methodology to analyze HS
preparations isolated from pulmonary fibroblasts and epithelial cells. Significant differences in the general organization of
these two HS preparations were observed, with HS from epithelial cells having a greater frequency of highly sulfated
domains. Epithelial HS also showed a higher density of specific HS domains that have been associated with inhibition of
neutrophil elastase. Experimental analysis of elastase inhibition was consistent with the model predictions and
demonstrated that HS from epithelial cells had greater inhibitory activity than HS from fibroblasts.
Conclusions/Significance: This model establishes the conceptual framework for a new class of computational tools to use
to assess patterns of domain organization within glycosaminoglycans. These tools will provide a means to consider high-
level chain organization in deciphering the structure-function relationships of polysaccharides in biology.
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Introduction
Complex glycans such as glycosaminoglycans (GAGs) are rapidly
becoming appreciated as major regulators of cell function
throughout the animal kingdom [1–3]. In particular, the GAG
chains of proteoglycans have been shown to play important roles in
mediating cell-extracellular matrix interactions, extracellular matrix
structure and function, and cell-cell communication principally
through the ability of GAGs to bind to a wide range of proteins
[4,5]. Heparan sulfate (HS), the most structurally diverse GAG
class, has been implicated in countless normal and pathological
biological processes [1,3,6,7]. HS is a linear polysaccharide
composed of repeating disaccharide units of hexuronic acid (D-
glucuronic acid or L-iduronic acid) and D-glucosamine (N-
unsubstituted, N-acetylated, or N-sulfated) with varying degrees of
O-sulfation. The disaccharides are clustered in alternating domains
of short segments of highly sulfated disaccharides (S-domains) and
longer segments of predominantly unmodified disaccharides [1,8,9].
Since the discovery that a rare sequence of five sugars in heparin is
responsible for the binding and functional modulation of anti-
thrombin III [10], substantial effort has focused on specifying the
sequences for other HS-protein interactions.
Although significant advances in the analytical methodology for
HS sequencing have been made in recent years [5,11–15], the
current level of technology still lacks the capability to ‘‘sequence’’
HS chains longer than a decasaccharide. Instead, typical HS
chains (25–200 disaccharides) are degraded with chemicals and
enzymes of known specificity into a population of smaller segments
that are separated by size and then purified and sequenced.
Successful sequencing of small oligosaccharides containing ten or
less sugars has been accomplished by a variety of techniques
ranging from gel electrophoresis and chromatography to mass
spectrometry (MS) and nuclear magnetic resonance (NMR)
spectroscopy.
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In a strategy called integral glycan sequencing (IGS), oligosac-
charides are labeled on the reducing end with a fluorescent tag,
partially cleaved with nitrous acid (low pH), and sequentially
processed with different exoenzymes [16,17]. The various stages of
digested oligosaccharides are separated by polyacrylamide gel
electrophoresis (PAGE), and the ladder-like pattern of fluorescent
bands from a single run is used to directly read the saccharide
sequence. Other methods follow a similar approach by labeling the
oligosaccharides with different tags (e.g., radiolabels) and using a
series of strong anion-exchange high-performance liquid chroma-
tography (SAX-HPLC) steps to separate and identify the digests
[18–20].
These relatively simple techniques of degradation and separa-
tion are frequently combined with more sophisticated instrumen-
tation and software programs in sequencing strategies. For
example, by integrating capillary electrophoresis (CE) with
matrix-assisted laser desorption ionization MS (MALDI-MS), a
list of all possible sequences for the oligosaccharide is generated
using a scheme based upon a property-encoded nomenclature
(PEN) [21,22]. Subsequent chemical or enzymatic degradations of
the oligosaccharide, followed by MALDI-MS identification of the
fragments, allow convergence to a unique sequence on the list. In a
related strategy using the PEN system, CE is paired with NMR
spectroscopy to deduce the oligosaccharide sequence by combin-
ing complementary information on linkages between adjacent
monosaccharides [23]. NMR data are acquired from a single
series of one-dimensional (1D) proton and two-dimensional (2D)
correlation spectroscopy (COSY)/total correlation spectroscopy
(TOCSY) experiments using the intact oligosaccharide without
need for further degradation. Another sequencing strategy
integrates electrospray ionization MS (ESI-MS) of the intact
oligosaccharide with ESI-MS and tandem MS (MSn) of the
exhaustively digested oligosaccharide through a software applica-
tion called the heparin oligosaccharide sequencing tool (HOST) to
generate all possible sequences [24]. These sequences are then
fragmented theoretically by the program, and product ions are
compared with experimental fragments from MSn of the
oligosaccharide to determine the best match.
Despite the continuing development of these analytical
methods, the reality of the situation is that only short oligosac-
charides can be fully sequenced, and the prospect of unmasking
the structure of intact HS chains remains a formidable challenge.
The original success of the heparin-antithrombin binding model,
however, is becoming somewhat tempered by the recognition that
the presence of distinct protein-specific saccharide sequences is
more likely the exception than the rule [3,5,9,12]. Although
studies indicate that particular sulfated residues are required or
more preferred in certain situations [25], protein binding may
ultimately depend on the ability to properly position these residues
with respect to complementary regions on the protein surface.
While flexibility of the iduronic acid ring enhances local fit
between binding partners, on a larger scale, this feature has
minimal influence on the orientation of the chain [26]. Instead, the
overall flexibility of the chain is defined by the spacing of the
unmodified domains. Thus, variations in domain spacing and
overall chain flexibility are likely to have dramatic effects on the
potential of an HS chain to bind and modulate proteins [1,26,27].
The lack of an analytical capability to detect patterns of HS
domain organization is a direct offshoot of the inability to fully
sequence the chain, and the consequence of this deficiency has
severely limited the understanding of HS structure-function
relationships at a mechanistic level [28]. As a result, alternative
approaches have been sought in an attempt to reveal information
regarding the larger picture of domain organization. For example,
an end-referencing approach was used to describe the domain
structure of the first 36 disaccharides of an HS chain [29], and
more recently, a method of selective lyase degradation was utilized
to predict an average spacing of 16–18 disaccharides between
highly sulfated domains [30]. However, there remains no
generalized conceptual approach for exploring patterns of HS
domain organization. Solutions to this challenge will require new
and creative tools as alternative sources of information.
To address this need, a novel computational approach was
developed for predicting the patterns of HS domain organization.
Using experimental data from disaccharide analysis and selective
heparin lyase digestion of HS samples, a computational routine
was devised to generate populations of predicted HS chains that
can be evaluated for the presence of general and specific structural
properties. The generated chains are transformed into strings of
user-defined domains and examined for patterns of domain
organization. The model was tested by applying it to the analysis
of two different samples of HS chains isolated from rat pulmonary
fibroblast and epithelial cell cultures. The results show significant
differences in the overall domain organization of these two samples
as well as in the density of a specific structural motif proposed to be
required for the inhibition of the inflammatory protease,
neutrophil elastase. The findings herein indicate that this approach
may provide an innovative tool for exploring the structural
distinctions in various HS populations (i.e., from different tissues,
organs, disease states, or stages of development) that could yield
insight into the mechanisms of HS control of important biological
processes.
Materials and Methods
Nomenclature
Disaccharides were designated by four alphanumeric characters
called the disaccharide structural code [31]. For the relevant HS
disaccharides of this study, the first two characters represent the
hexuronic acid—a letter for the stereochemistry (D = unsaturat-
ed; G = glucuronic; I = iduronic) and a number for the location
of O-sulfation (0 = no sulfation; 2= 2-O-sulfation), and the last two
characters represent the glucosamine—a letter for the N
substituent (H = free amine or N-unsubstituted; A = N-
acetylated; S = N-sulfated) and a number for the location of O-
sulfation (0 = no sulfation; 6= 6-O-sulfation).
Materials
Heparin (porcine intestinal mucosa; 17–19 kDa), chondroitin-4-
sulfate, and 1,9-dimethylmethylene blue were from Sigma-Aldrich
(St. Louis, MO). Heparan sulfate (porcine intestinal mucosa; 8–
10 kDa) was obtained from Neoparin (Alameda, CA). Human
neutrophil elastase (human purulent sputum; 29.5 kDa) and
elastin (bovine neck ligament; particle size ,37 mm) were
purchased from Elastin Products Company (Owensville, MO).
Dulbecco’s phosphate-buffered saline (PBS) without calcium and
magnesium salts was ordered from Invitrogen (Carlsbad, CA).
Chemical Structure Analysis of HS Preparations
Purified HS preparations were isolated from rat pulmonary
fibroblasts [32] and epithelial cells [33] according to published
methods [34]. Lyophilized samples of HS chains were sent to the
Glycotechnology Core Resource at the University of California,
San Diego (La Jolla, CA), for a series of heparin lyase digestions
followed by HPLC profiling of the disaccharide products. All
digestions were performed at 37uC overnight, and the resulting
data are tabulated in Tables 1 and 2. The first set (Table 1) is the
total disaccharide composition of each sample after exhaustive
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digestion with heparin lyases I, II, and III. The second set (Table 2)
represents an attempt to mimic a sequential-like digestion by
dividing each sample into three parts and digesting the first with
heparin lyase III, the second with heparin lyases I and III, and the
third with heparin lyases I, II, and III. The values in the table are
the cumulative percentage of each disaccharide released after each
digestion ‘‘step.’’
Neutrophil Elastase Inhibition
The ability of various GAG preparations to inhibit the activity
of human neutrophil elastase (HNE) was evaluated with an in vitro
elastin digestion assay. Inhibitor stock solutions in PBS were made
for two commercial products, heparin and heparan sulfate (85 mg/
mL), and for two HS preparations from rat pulmonary fibroblasts
and epithelial cells (85 mg GAG/mL; determined using the
dimethylmethylene blue assay with chondroitin-4-sulfate standards
[35]). A quantity (63 mL) of inhibitor stock or PBS was added with
vortexing to tubes containing 1 mL of elastin suspension (1.0 mg/
mL in PBS), and after 30 minutes at room temperature, a quantity
(10 mL) of HNE stock (12.9 mM in PBS) or PBS was added. The
resulting set of samples consisted of duplicates of elastin alone,
elastin with HNE, and elastin with HNE plus inhibitor at final
concentrations of 0.93 mg/mL elastin, 120 nM HNE, and
5.0 mg/mL inhibitor. The tubes were slowly rotated (6 rpm) for
4 hours at 37uC, and the contents were transferred to filter units
(Millipore Ultrafree-CL, 0.22 mm) for centrifugation at 3000 g for
4 minutes at 4uC. The filtrates (500 mL) were transferred to empty
tubes for determination of soluble elastin with the Fastin Elastin
assay kit (Biocolor, Carrickfergus, UK). An equal volume of an
elastin precipitating reagent was added to each tube with vortexing
and allowed to set for 10 minutes. The precipitated elastin was
packed by centrifugation (10,000 g, 10 min) and drained of liquid.
One milliliter of dye reagent containing TPPS (5,10,15,20-
tetraphenyl-21,23-porphine tetrasulfonate) was added to each
tube with vortexing. The tubes were covered with foil and placed
on an orbital mixer (150 rpm) for 90 minutes at room
temperature. The insoluble elastin-dye complex was collected by
centrifugation (10,000 g, 10 min), drained of liquid, and destained
with 250 mL of a dye dissociation reagent. The solutions of
recovered dye were transferred to a 96-well microplate and read at
513 nm on a SpectraMax 190 microplate reader (Molecular
Devices, Sunnyvale, CA). Absorbances of duplicate samples were
averaged and corrected by subtracting the elastin control, and
elastin content was determined from a standard curve (0–70 mg)
based on a-elastin supplied with the kit. The quantity of elastin in
the samples was used to calculate values of relative rate (elastin
digestion with inhibitor/elastin digestion without inhibitor) for
comparing the effect of each GAG preparation on HNE activity.
Estimation of Hexuronic Acid Epimeric Fractions
The glucuronic acid and iduronic acid components of the
unsaturated disaccharides from heparin lyase digestion are listed in
Table 3. These epimeric fractions were estimated from published
data on the degradation of bovine lung HS [36]. In this reference,
disaccharides were measured after three reactions: hydrazinolysis
followed by nitrous acid deaminative cleavage at pH 1.5 and 3.9
(reaction 1), nitrous acid deaminative cleavage at pH 1.5 (reaction
2), and exhaustive digestion with a mixture of heparin lyases
(reaction 3). In reaction 1, the anhydromannose disaccharides
provided glucuronic acid/iduronic acid fractions (XG, XI) for all N-
unsubstituted (H), N-acetylated (A), and N-sulfated (S) disaccha-
rides of a particular O-sulfation in the chain. The anhydroman-
nose disaccharides from reaction 2 gave glucuronic acid/iduronic
acid fractions (xGS, xIS) for N-sulfated disaccharides of a particular
O-sulfation in N-sulfated blocks, and this was assumed represen-
tative of the overall chain. The unsaturated disaccharides from
reaction 3 were a source of fractions for N-unsubstituted, N-
acetylated, and N-sulfated disaccharides (YH, YA, YS) of a particular
O-sulfation in the chain. With this information, it was possible to
write a mass balance on disaccharides with the same degree of O-
sulfation for either glucuronic acid
XG~xGHYHzxGAYAzxGSYS ð1Þ
or iduronic acid
XI~xIHYHzxIAYAzxISYS, ð2Þ
where xGH and xIH are fractions of glucuronic acid and iduronic
acid, respectively, for N-unsubstituted disaccharides of a particular
Table 1. Total disaccharide composition of HS samples after
exhaustive digestion.
HS sample D0H0 D0A0 D0S0 D0A6 D0S6 D2S0 D2S6
Fibroblast 0.8 61.3 18.6 12.0 1.8 3.8 1.7
Epithelial 1.0 59.8 19.2 7.5 1.7 8.2 2.4
Each HS sample was exhaustively digested with heparin lyases I, II, and III at
37uC overnight. Values represent the mole percentage of total disaccharides.
doi:10.1371/journal.pone.0009389.t001
Table 2. Cumulative percentage of disaccharides released
after sequential-like digestions of HS samples.
HS sample D0H0 D0A0 D0S0 D0A6 D0S6 D2S0 D2S6
Fibroblast
Heparin lyase III 87.6 79.8 81.4 34.7 31.4 0.0 0.0
Heparin lyases I, III 100.0 80.4 100.0 50.7 100.0 55.3 100.0
Heparin lyases I, II, III 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Epithelial
Heparin lyase III 79.8 66.2 73.2 42.2 20.9 0.0 0.0
Heparin lyases I, III 100.0 71.8 85.6 56.0 86.0 43.3 66.3
Heparin lyases I, II, III 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Each HS sample was divided into three parts. The first was digested with
heparin lyase III, the second with heparin lyases I and III, and the third with
heparin lyases I, II, and III. Digestions were performed at 37uC overnight. Values
represent the cumulative mole percentage of each disaccharide released after
each sequential-like digestion step.
doi:10.1371/journal.pone.0009389.t002
Table 3. Estimated fractions of glucuronic acid and iduronic
acid in unsaturated HS disaccharides.
Hexuronic acid D0H0 D0A0 D0S0 D0A6 D0S6 D2S0 D2S6
Glucuronic 1.00 0.99 0.83 0.54 0.61 0.01 0.00
Iduronic 0.00 0.01 0.17 0.46 0.39 0.99 1.00
Epimeric fractions were estimated from experimental data on bovine lung HS
[36] as described in Materials and Methods. Values represent the mole fraction
of each disaccharide that is glucuronic acid or iduronic acid.
doi:10.1371/journal.pone.0009389.t003
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O-sulfation, and xGA and xIA are fractions of glucuronic acid and
iduronic acid, respectively, for N-acetylated disaccharides of a
particular O-sulfation.
In the study on bovine lung HS [36], N-unsubstituted
glucosamine was not detected in the analysis of the unsaturated
disaccharides from reaction 3. This information (YH=0) was used
with the other data in the report to solve Equations 1 and 2 for the
glucuronic acid/iduronic acid components of disaccharide groups
containing N-acetylated glucosamine (D0A0 and D0A6). For
D0A0, a mass balance was written on all non-O-sulfated
disaccharides, and for D0A6, a mass balance was written on all
6-O-sulfated disaccharides. The determination of the glucuronic
acid/iduronic acid components for disaccharide groups with N-
sulfated glucosamine (D0S0, D0S6, D2S0, and D2S6) was
straightforward, using the reported data from reaction 2 [36].
The remaining disaccharide group containing N-unsubstituted
glucosamine (D0H0) was assumed to be all glucuronic acid.
Heparin Lyase Specificities
The 12612 cleavage matrices for heparin lyases I and III are
shown in Figure 1. For each matrix, the rows (i) and columns (j) are
assigned to the 12 disaccharides identified by Table 3, and each
cell (i, j) represents a linkage between disaccharides i and j, with j
being the downstream disaccharide (closer to the tetrasaccharide-
protein linker). Some linkages (crosshatched cells) are prohibited
by the rules of biosynthesis (rows 1, 2, 4, 7, and 9 in the right half
of the matrix), and other linkages (turquoise cells) are outside the
rules of lyase specificity. The entry in each cell indicates the
probability of cleavage by the lyase of interest. Wherever possible,
these values were adapted from reported data on the fractional
conversion of substrates containing the linkages [37,38]. Values of
complete conversion were adjusted to 0.9 to allow for some
randomness in the simulated cleavage process. When conflicting
information was found in the literature, the most inclusive rules for
lyase specificity were selected [30,39–42].
The cleavage matrix for heparin lyase I in Figure 1A reflects a
specificity for iduronic acid in the downstream disaccharide
[37,40]. Although evidence suggests that cleavage also occurs with
G2S6 on the downstream side [42], this disaccharide was absent
from the HS composition (Table 3). Accordingly, all entries in the
left half of the matrix (columns 1–6) were set to zero. Five linkages
(S0-I2, S6-I0A6, S6-I0S6, S6-I2S0, and S6-I2S6) were assigned
cleavage probabilities from 0.2 to 0.9 based on reported
degradation of defined oligosaccharides [38]. Other linkages
containing unsulfated iduronic acid (S0-I0, S6-I0A0, and S6-
I0S0) were given a nominal probability of 0.1.
Figure 1B shows the cleavage matrix for heparin lyase III. The
specificity of this lyase requires a downstream disaccharide
containing either unsulfated glucuronic acid (primary site) or
unsulfated iduronic acid (secondary site) [37,38,42]. As a result of
this requirement, the entries in columns 6, 11, and 12 of the
cleavage matrix were set to zero. Cleavage probabilities for other
cells were established from experimental degradation results on
defined oligosaccharides containing four linkages (S0-G0, A6-G0,
S6-G0, and S6-I0) [38]. These probabilities ranged in value from
0.5 to 0.9. For several linkages (H0-G0, A0-G0, and S0-I0),
comparable data were not found, and probabilities were estimated
at values from this range.
The cleavage matrix for heparin lyase II is not shown because
all the entries were adjusted to a value of 1. As the least
discriminating of the lyases [37], this enzyme was restricted to the
last position in the simulated digestion sequence. Consequently,
the lyase was assumed to finish the degradation of the HS chain
and was allowed to break every intact disaccharide-disaccharide
bond. This assumption seemed reasonable since exhaustive
digestion with all three lyases is a common preparatory procedure
for determining the disaccharide composition of HS oligosaccha-
rides. However, if heparin lyase II were applied at an earlier step
in the sequential digestion, the cleavage matrix would require
Figure 1. Heparin lyase cleavage matrices for HS disaccharide-
disaccharide linkages. (A) Estimated cleavage probabilities for
heparin lyase I. (B) Estimated cleavage probabilities for heparin lyase
III. Each cell in (A) and (B) represents a disaccharide-disaccharide
linkage with an indicated probability of cleavage by the specific heparin
lyase. Turquoise cell = linkage not cleaved by lyase. Crosshatched
cell = linkage prohibited by rules of biosynthesis.
doi:10.1371/journal.pone.0009389.g001
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some modification to more accurately reflect the action of this
lyase.
Computational Analysis of HS
The computational approach for predicting patterns of HS
domain organization was driven by experimental inputs and user-
defined rules of HS biosynthesis and lyase breakdown. In its
present form, the model uses the total disaccharide composition
determined after complete lyase digestion and the relative amounts
of various disaccharides released after individual or sequential
lyase digestion in conjunction with average chain length
measurements to build populations of theoretical HS chains to
represent the original HS sample. These HS chain populations are
then evaluated for structural patterns of domain organization. The
model performs these operations through a modular format
consisting of input/output sections and three routines called
chainmaker, chainbreaker, and chainsorter.
Input. The input section of the computational model requires
information on (a) the number of disaccharides in the chain, N, (b)
the number of chains, M, (c) the total disaccharide composition
with glucuronic acid/iduronic acid specifications, (d) the order of
heparin lyase digestion, (e) the breakdown constraints for matching
simulated and real results of disaccharide release after each
digestion step, and (f) the specific disaccharides that define each
domain.
Chainmaker routine. The chainmaker routine (Figure 2A)
creates an HS chain of specified length and composition with
disaccharides situated in positions that satisfy known rules of
biosynthesis. In step 1 of the routine, a base chain is generated
containing N units of unmodified disaccharide (G0A0) (see
definition of nomenclature in Materials and Methods). The
actual disaccharides in the chain are calculated from the total
disaccharide composition, and these disaccharides (except for
G0A0) are placed into a selection pool. A disaccharide is randomly
selected from the pool, and a position on the chain is randomly
chosen (step 2). If G0A0 exists in the selected chain position and N-
unsubstituted glucosamine is not on the upstream side (farther
from the tetrasaccharide-protein linkage), the selected disaccharide
replaces G0A0. If N-unsubstituted glucosamine is on the upstream
side of the position, the selected disaccharide must contain
glucuronic acid in order to replace G0A0. If any of these
conditions is not satisfied, another position is randomly chosen for
the disaccharide until a successful replacement occurs.
Once the selected disaccharide is placed on the chain, it is
subjected to another set of positional constraints (step 3). These
constraints are adapted from reported observations on HS
biosynthesis [8,36,37,43] and consist of the following: (a) a
disaccharide with either iduronic acid or 2-O-sulfation must have
N-sulfated (66S) glucosamine on the upstream side, (b) a
disaccharide with 6-O-sulfation must have at least one adjacent
disaccharide with N-sulfated (66S) glucosamine, and (c) a disaccha-
ride with N-unsubstituted glucosamine must have glucuronic acid on
the downstream side. If the positional constraints are met, the
disaccharide remains on the chain (step 4); otherwise, the
disaccharide returns to the pool, G0A0 refills the vacated spot, and
the selection process starts over. Eventually, all disaccharides from
the pool are placed on the chain, and the resulting chain has a
disaccharide composition compatible with the original input (step 5).
Chainbreaker routine. The chainbreaker routine (Figure 2B)
determines whether a newly created chain (step 6) is acceptable by
subjecting the chain to simulated digestions and comparing the
released disaccharides with breakdown constraints. The chain is
exposed to sequential digestion by heparin lyases in a specified order
(III, I, II or I, III, II). In the first digestion step (step 7), the linkage
between the first and second disaccharides on the chain is assigned a
probability of cleavage based on the specificity of the particular lyase
[30,37–42] (Figure 1 and Materials and Methods). A random
number is generated, and if it is less than or equal to the assigned
probability, the bond is broken. This process is repeated along the
chain, assessing each disaccharide-disaccharide linkage, until the
end is reached. The chain is re-examined for all broken bonds (step
8), and if cleavage occurs on both sides of a disaccharide, that
disaccharide is considered ‘‘released.’’ The second digestion step is
Figure 2. Schematic diagrams of chainmaker and chainbreaker
routines for generating HS chains. (A) Chainmaker routine: (1)
creates a base chain of N units of G0A0; (2) selects a disaccharide
randomly from a pool based on experimental composition and places
the disaccharide at a random position on the chain; (3) checks the
positional constraints for disaccharide placement; (4) repeats steps 2–3
until placement occurs; (5) repeats steps 2–4 until all disaccharides from
the pool are placed on the chain. The completed chain moves to the
chainbreaker routine. (B) Chainbreaker routine: (6) receives the
completed chain from the chainmaker routine; (7) initiates the first
digestion (heparin lyase I or III) by comparing a random probability with
the cleavage probability of each bond; (8) determines the broken bonds
and releases disaccharides with cleavage on both sides; (9) repeats
steps 7–8 for the second digestion; (10) cleaves all remaining bonds and
releases all remaining disaccharides in the final digestion (heparin lyase
II); (11) compares the released disaccharides from the first two
digestions with the experimental breakdown constraints. If the
constraints are satisfied, the successful chain moves to storage.
doi:10.1371/journal.pone.0009389.g002
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then activated (step 9), and the chain is reprocessed with a new set of
cleavage probabilities appropriate for the lyase of the step. Finally,
in the last digestion step (step 10), all bonds remaining in the chain
are broken.
The disaccharides released in each of the first two digestion
steps are compared with the experimental products of sequential
digestion, and if they fall within the allowable limits (breakdown
constraints), the chain is designated as a successful chain (step 11).
If any constraint is not met, the chain is discarded, and the
program returns to the chainmaker routine to generate a new
chain. The program cycles between chainmaker and chainbreaker
routines until M successful chains are generated.
Chainsorter routine. The chainsorter routine transforms
each successful chain into a string of user-defined domains. Each
chain is processed disaccharide by disaccharide, classifying the
disaccharide into the appropriate domain and keeping track of the
length and order of the contiguous stretches of each domain along
the chain.
Output. The output section of the model generates files that
contain the following: (a) a list of successful chains in the form of
sequences of numbers, each number representing a particular
disaccharide, (b) a list for each domain giving a sequence of
numbers for each chain, where each number indicates the domain
length in disaccharides sequentially along the chain, and (c) a
summary containing the successful chains, the disaccharide
breakdown of these chains after specific lyase digestion, and the
average domain lengths within these chains.
Computer Program
A computer program of the model was written in Fortran 95
using Absoft Pro Fortran software (Absoft, Rochester Hills, MI)
and supported by the IMSL Fortran Library (Visual Numerics,
Houston, TX). Pseudorandom uniform numbers were generated
using a generalized feedback shift register to avoid cycling issues.
This generator was essential for building unique chains; for
example, approximately one million chains were required in order
to produce 100 successful chains (no duplicates) of 250
disaccharides for fibroblast HS. The program was compiled and
executed on a personal computer operating under Windows XP
(Microsoft, Redmond, WA) with an Intel Core 2 Quad processor
(Intel, Santa Clara, CA) at 2.40 GHz (3.50 GB of RAM).
Execution times varied from less than one minute to more than
two days, depending on the values for chain length, chain number,
and breakdown constraints.
Domain Analysis
The average domain size in disaccharides for chains of equal
length was calculated by determining the average domain size for
each chain and then averaging these values over all the chains in
the set. The 95% confidence interval for the average domain size
was estimated from the standard error of the mean and the
Student’s t-distribution. The characteristics of the plateau region
(equilibrium domain size; critical length) were determined by a
one-way analysis of variance (alpha = 0.05) of the points in each
plot. If there was a statistical difference (p,0.001), a pairwise
multiple comparison using the Holm-Sidak method (overall
significance level = 0.05) was performed. The points that showed
no statistical differences among themselves were averaged to
obtain the equilibrium domain size, and the shortest chain length
in the group was designated as the critical length for stabilization
of the domain. To determine if there were statistical differences
(p,0.001) between the domains of the two sets of HS chains, a t-
test was performed (alpha = 0.05) on the less sulfated domains and
on the highly sulfated domains.
Fourier Analysis
Fourier analysis was completed on a set of M chains of length N
disaccharides, where N is a power of 2. The disaccharide sequence
of each chain was converted into a binary sequence representing
the domains of interest [44,45]. A fast Fourier transform routine in
Microsoft Office Excel 2003 was applied to each binary sequence
to yield a set of N complex coefficients
cmk~
1
N
XN{1
n~0
xmne
{2pink=N , k~ 0, . . . ,N{1, ð3Þ
where k is the wavenumber, k/N is the spatial frequency, and xmn is
a component in the binary sequence m (m=1, …, M) at position n
(n=0, …, N-1). For frequencies above the base frequency (k=0),
the power spectrum for each sequence was calculated as the square
of the magnitude of the Fourier coefficients
Smk~ cmkj j2: ð4Þ
An average power spectrum for a set of M spectra [46] was
defined as a frequency by frequency average over all spectra
Sk~
1
M
XM
m~1
Smk: ð5Þ
For each HS sample, 100 chains were generated having a length
equal to the smallest power of 2 above the critical length. Each
chain was converted into a binary sequence by substituting 1 for
disaccharides in the highly sulfated domain and 0 for disaccharides
in the less sulfated domain. The Fourier coefficients (Equation 3)
and the resulting power spectrum (Equation 4) were calculated for
each binary sequence, and the power spectra were averaged
(Equation 5), starting with 10 chains and increasing in 10-chain
increments to 100 chains, to determine a set of average power
spectra for each HS sample. Each average power spectrum was
normalized with respect to the highest response and plotted to
show only the first half of the symmetric trace (k=1, …, N/2). A
prominent peak at a wavenumber of k signifies a periodic structure
in the chain consisting of N/k disaccharides. The power at k=0
contains no information on position and was disregarded for this
analysis.
Results
Computational Analysis of HS Preparations
HS chains from rat pulmonary fibroblasts and epithelial cells
[34] were subjected to chemical compositional analysis, and the
data were used to generate predicted chain structures using the
computational model. The experimental data consisted of the total
disaccharide composition after digestion with heparin lyases I, II,
and III (Table 1) and the percentage of each disaccharide released
after sequential-like digestions with heparin lyases III, I, and II
(Table 2). Epimeric fractions (Table 3) were estimated from
published data [36] and used to proportion the unsaturated
disaccharides in Table 1 into glucuronic acid and iduronic acid
components. Three groups (D0A0, D0A6, and D2S0) in Table 2
were chosen for comparison with the simulated disaccharide
release, and practical tolerances for the breakdown constraints
were set at D0A0 62%–4%, D0A6 620%, and D2S0 60% for
each of the first two digestion steps. The resultant output from the
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model was a series of chains of a given length and disaccharide
sequence that were consistent with the experimental data (Tables 1
and 2). The chains were analyzed in several ways to predict
general patterns of domain organization as well as the distribution
and density of specific structural motifs within the two HS
populations.
Predictions of General Patterns
HS structure has been described as being comprised of
alternating domains of highly sulfated regions (S-domains)
separated by less sulfated regions (NA-domains) which are
generally connected by regions containing intermediate levels of
sulfation (transition domains). However, HS domains can be
arbitrarily specified to include any defined structures of particular
disaccharides. Thus, as a first approximation for this analysis,
domains were defined simply as being one of two regions—a
highly sulfated domain containing disaccharides with 2-O-sulfated
iduronic acid (Figure 3A) and a less sulfated domain containing all
other disaccharides. Consequently, the less sulfated domain
contains not only unsulfated disaccharides but also some sulfated
disaccharides (e.g., I0S0, I0S6, and G0A6). In terms of commonly
used nomenclature, the highly sulfated domain is most similar to
the S-domain, and the less sulfated domain encompasses both the
NA-domain and the transition regions [30].
Examples of 250-disaccharide chains with alternating regions of
highly sulfated domains (yellow blocks) and less sulfated domains
(blue blocks) are illustrated for both fibroblast and epithelial HS
chains (Figure 3B). The less sulfated domains exhibited a wide
range of sizes (1–113 disaccharides) while the highly sulfated
domains were more limited in size (1–4 disaccharides). Compar-
ison of the size distributions of the less sulfated domains (Figure 3C)
for 100 chains of each sample shows a larger fraction of shorter
domains (below 10 disaccharides) for epithelial HS chains and a
larger fraction of longer domains (above 20 disaccharides) for
fibroblast HS chains. For a more in-depth analysis of the overall
patterns of domain organization that characterize these chains,
two analytical methods were applied to the output. The first
method was a relatively straightforward technique using average
domain sizes, and the second method was a more sophisticated
technique of pattern recognition using Fourier analysis.
Average domain sizes. The simple determination of average
domain sizes requires a sufficient number of chains to achieve a
reasonable level of consistency in the predicted results. A series of
runs was completed in which 5 to 400 chains of various lengths
were generated for both fibroblast and epithelial samples. The
results for the shortest chains (50 disaccharides) and the longest
chains (250 disaccharides) are shown in Figure 4A, where the
uncertainty in the average size of the less sulfated domain is plotted
as a function of the number of generated chains. Although the
uncertainty was as high as 18% for 10 or less chains, the
generation of at least 100 chains reduced the uncertainty to less
than 5%. Further increases in the number of chains decreased the
uncertainty even more, but this gain was offset by growing
computational time. Based on these results, the generation of 100
chains guaranteed a reasonable run-to-run consistency, and all
subsequent executions were carried out with this number of
chains.
Analysis of the average size of the less sulfated domain as a
function of chain length (Figures 4B and 4C) revealed the same
overall trend for both samples—domain size increased with
increasing chain length until a critical length was reached, after
which the domain size remained relatively constant. For fibroblast
HS chains (Figure 4B), this critical chain length was 250
disaccharides, and the equilibrium domain size was 20.160.1
Figure 3. General patterns of domain organization predicted
for fibroblast HS and epithelial HS. (A) Chemical structure of the
disaccharide containing 2-O-sulfated iduronic acid that defines the
highly sulfated domain. All other disaccharides, including the remaining
sulfated disaccharides, belong to the less sulfated domain. (B)
Schematic diagram of HS chains showing domain organization. Yellow
blocks are highly sulfated domains; blue blocks are less sulfated
domains. Chain lengths are 250 disaccharides. Minimum block length is
1 disaccharide. (C) Size distribution of less sulfated domains in HS
chains. N = 250 disaccharides and M = 100 chains. Although the
distribution is shown for less sulfated domains up to 80 disaccharides
in length, a few longer domains are present in both sets of HS chains.
For epithelial HS, less sulfated domains extend to 87 disaccharides; for
fibroblast HS, less sulfated domains extend to 113 disaccharides. Dashed
lines indicate average sizes: E=11.460.2 disaccharides (average 695%
confidence limits) for epithelial chains and F=20.060.4 disaccharides for
fibroblast chains.
doi:10.1371/journal.pone.0009389.g003
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disaccharides (average 695% confidence limits). For epithelial HS
chains (Figure 4C), the critical chain length occurred at a much
shorter 100 disaccharides, and the equilibrium domain was much
smaller at 11.260.2 disaccharides. In contrast, the size of the
highly sulfated domain remained relatively stable regardless of
chain length. The equilibrium size was 1.2260.02 and 1.3860.02
disaccharides for fibroblast and epithelial HS chains, respectively
(Figures 4B and 4C). The equilibrium sizes of both the less sulfated
domains and the highly sulfated domains were significantly
different (p,0.001) between the two HS samples. A comparison
of the resulting patterns of these domains in a fibroblast HS chain
and an epithelial HS chain above the critical length reveals that
the epithelial HS chain has a greater frequency of highly sulfated
domains separated by shorter segments of less sulfated domains
(Figure 4D).
Fourier analysis. Because discrete Fourier transform
analysis has been successfully used to detect periodical properties
in DNA and protein sequences [45,46], this technique was
examined as an alternative method for discerning general patterns
of domain organization in HS chains. For each HS sample, 100
chains were generated, and the average Fourier power spectrum
was calculated for a variable number of chains, starting at 10 and
increasing by increments to 100. A few examples of the resulting
power spectra for each group of HS chains are depicted in
Figure 5.
The average power spectra for fibroblast HS chains of 256
disaccharides consistently showed a dominant peak at a wave-
number of k=12 or 13 (Figures 5A, 5C, and 5E). This peak was
visible in all the average spectra from as few as 10 chains to as
many as 100 chains. The peak wavenumbers indicate a periodic
component (N/k) with a length of 20–21 disaccharides. This size is
in good agreement with the equilibrium domain sizes (Figure 4B),
where the length of one highly sulfated domain followed by one
less sulfated domain is 21 disaccharides.
The patterns of the average power spectra for epithelial HS
chains of 128 disaccharides were more complex to interpret
(Figures 5B, 5D, and 5F). The average spectra showed two peaks
at k=8 and 12 that were predominant in the majority of the
spectra. These wavenumbers represent periodicities of 16 and 11
disaccharides, suggesting a mixture of two patterns. Remarkably,
the average of these two numbers compares favorably with the
periodic spacing of 13 disaccharides predicted from the equilib-
rium domain sizes (Figure 4C).
Predictions of Specific Motifs
Some activities of HS are likely related to the general
organization of the chains, while others are dependent on the
presence of specific local structural motifs. As an extreme example,
the ability of heparin to bind to antithrombin III is dependent on
the presence of a rare pentasaccharide structure [10], whereas
most other protein interactions seem to involve less stringent
criteria [3,5,9,12]. The ability of the computational model to
predict the arrangement of particular structural motifs was
evaluated by analyzing the HS chains for the presence of
structures associated with elastase inhibition.
Heparin is a potent inhibitor of neutrophil elastase [47–50]. In
particular, the inhibition of elastase-mediated solubilization of
elastin has been shown to depend on both the presence of sulfated
disaccharides and the length of the chain [48]. The removal of 2-
O-sulfate from the hexuronic acid residues in heparin reduced
inhibitory activity by 20%, while the removal of 6-O-sulfate or N-
sulfate from the glucosamine residues resulted in approximately
50% and 70% loss of inhibitory activity, respectively [48].
Examination of the molecular structure of heparin [26] revealed
Figure 4. Average domain sizes predicted for fibroblast HS and
epithelial HS chains. (A) Uncertainty in average domain size of less
sulfated domains as a function of chain number. N=50 and 250
disaccharides; M=5–400 chains. % Uncertainty = [(695% confidence
limits)/(average domain size)]6100. (B) Average domain size as a function of
chain length for fibroblast HS. (C) Average domain size as a function of chain
length for epithelial HS. N=25–450 disaccharides andM=100 chains for (B)
and (C). Error bars show 95% confidence interval. (D) Schematic diagram of
chains showing predicted domain patterns. Yellow blocks are highly sulfated
domains; blue blocks are less sulfated domains. Each chain is above the
critical length, and domain sizes are equilibrium values. For fibroblast HS, less
sulfated domain =20.160.1 disaccharides (average 695% confidence
limits) and highly sulfated domain =1.2260.02 disaccharides. For epithelial
HS, less sulfated domain =11.260.2 disaccharides and highly sulfated
domain =1.3860.02 disaccharides.
doi:10.1371/journal.pone.0009389.g004
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Figure 5. Examples of average Fourier power spectra for HS chains. Average power spectrum for fibroblast HS based on (A) 20 chains, (C) 40
chains, and (E) 60 chains. N= 256 disaccharides. Average power spectrum for epithelial HS based on (B) 20 chains, (D) 40 chains, and (F) 60 chains.
N=128 disaccharides. Each spectrum is normalized with respect to the highest response and is shown for the first half of the symmetric trace (k= 1,
…, N/2).
doi:10.1371/journal.pone.0009389.g005
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that these three sulfate groups form a cluster that alternates from
side-to-side along the length of the chain. The sulfate cluster is
composed of two sequential disaccharides on the chain—a
disaccharide with 2-O- and 6-O-sulfation followed by an upstream
disaccharide with N-sulfation. Molecular-docking simulations
suggested that these sulfate clusters bind to positively charged,
clamp-like regions on elastase that span the active site [48].
According to this bridging model, appropriately sized heparin
chains would tend to block the active site and cause inhibition,
whereas shorter chains would be unable to span the site. Longer
chains would provide increased stability in blocking the active site
and might eventually encourage translation of the elastase
molecule along the chain, thus contributing to an increased
inhibitory response with increased chain length. This proposed
mechanism was supported by experimental results with heparin
oligosaccharides. No significant effect on elastolysis was detected
until the chain reached a length of about 6 disaccharides (16%
inhibition), and this effect increased by more than three times
(51% inhibition) with the addition of one disaccharide to the
chain. Although longer oligosaccharides (greater than 7 disaccha-
rides) were not tested, inhibitory activity leveled off at about 92%–
95% with heparin preparations having average chain lengths of
24–30 disaccharides [48].
On the basis of this information, search criteria were specified
for elastase inhibitory motifs in HS chains. A pattern was defined
as a sulfate cluster (cluster domain) containing a pair of
disaccharides, with I2S6 as the downstream disaccharide and N-
sulfated disaccharide as the upstream disaccharide (Figure 6A),
separated by 2–20 disaccharides (connector domain) from the next
sulfate cluster. Cluster/connector/cluster motifs having connector
domains larger or smaller than this range were considered
ineffective for elastase inhibition. Even though there was no
experimental evidence in support of this size constraint for
effective elastase inhibitory motifs in HS chains, the existence of
limits seemed reasonable based on structural considerations. For
example, a connector domain of less than 2 disaccharides would
create a cluster/connector/cluster length of less than 6 disaccha-
rides. A chain section with this specific motif would have difficulty
in physically spanning the active site of elastase as suggested by the
bridging model for heparin inhibition [48]. Longer connector
domains would allow this bridging to take place with subsequent
disruption of elastase activity. However, at some point, unlike the
heparin chain, the connector domain would become too long,
leading to reduced effectiveness of the HS chain. The proposed
divergence from the trend observed with heparin oligosaccharides
was attributed to the alternating domain structure of the HS chain.
In contrast to the relatively rigid heparin chain, the HS chain
would have increased flexibility because of the less sulfated and
therefore less constrained connector domains [1,26,27]. For an HS
chain in the bridging formation, a flexible connector domain
would have less likelihood of remaining in close proximity to the
elastase surface. This situation would allow substrate access to the
active site, a condition that would become worse with increasing
size of the connector domain. In fact, a long connector domain
might even prevent the cluster domains from binding to the
requisite elastase regions for bridging the active site. The upper
limit of the effective connector domain was set to a relatively high
value of 20 disaccharides as a first step in the analysis. The
resulting cluster/connector/cluster motif of 24 disaccharides
agreed with the average chain size of an experimentally evaluated
heparin preparation that was an effective elastase inhibitor [48].
Sequences from the 250-disaccharide chains generated for
Figure 3B were searched for the distinctive cluster/connector/
cluster pattern of the elastase inhibitory motif. Examples of 10
chains from each HS sample are illustrated in Figure 6B, showing
cluster domains (yellow blocks), connector domains (blue blocks),
and connector domains that meet the size requirement of the
pattern (dark blue blocks). Comparison of the two sets of chains
clearly shows that epithelial HS contained more chains with the
elastase inhibitory motif and more instances of this motif per chain
than fibroblast HS. The statistics for 100 chains confirmed these
findings, indicating that 89% of epithelial chains and 54% of
fibroblast chains had the motif, and within those selected chains,
58% of epithelial chains and 24% of fibroblast chains had more
than one occurrence of the motif. Figure 6C shows the size
distribution of connector domains in the 100 chains generated for
each HS sample. Although the plots are shown for connector
domains up to 100 disaccharides in length, the actual distributions
extend past this cut-off for both sets of chains. The average
connector domain size (average 695% confidence limits) was
3663 disaccharides for epithelial HS and 5265 disaccharides for
fibroblast HS. The crosshatched bars represent the connector
domains that fit the requirements for the elastase inhibitory motif.
They indicate that epithelial HS had more than twice as many of
these motifs as fibroblast HS. This same trend was observed in the
subset of domains with connector lengths of 2–10 disaccharides.
Although the original limits on the connector domain were
generously set at 2–20 disaccharides, the lower end (2–10
disaccharides) is more likely to be the functional range for
inhibition based on elastase structural considerations.
Elastase Inhibition by HS Preparations
Based on the relative density of the elastase inhibitory motif, the
model results predict that epithelial HS would be a more potent
inhibitor of elastase than fibroblast HS. This prediction was tested
by measuring elastase activity in the presence of various GAG
preparations consisting of commercial heparin and heparan sulfate
and HS preparations derived from rat pulmonary fibroblasts and
epithelial cells. The results from the experiments are presented in
Figure 6D in terms of the relative rate of reaction (elastin digestion
with inhibitor/elastin digestion without inhibitor). As expected,
heparin was a potent inhibitor of elastolysis (92% inhibition) while
heparan sulfate was less active (22% inhibition). Interestingly, the
HS preparations from the pulmonary cells showed differences
consistent with the model predictions. Whereas the HS prepara-
tion from the fibroblasts reduced elastase activity by only 17%, the
epithelial HS preparation was significantly more effective at 49%
inhibition.
Discussion
Glycans are a diverse group of carbohydrates that play an intricate
role in fundamental physiological processes through their modulation
of protein activity and their ability to fine-tune biological responses
[4]. Sulfated glycosaminoglycans represent a group of linear sugars
that are incorporated as proteoglycans at the surfaces of cells and in
the extracellular matrix. GAGs positioned at the cell-extracellular
matrix interface have a unique opportunity to interact with a wide
spectrum of proteins, including growth factors, cytokines, chemo-
kines, morphogens, proteases, antiproteases, cell adhesion molecules,
and extracellular matrix components [1,8]. The resulting GAG-
protein interactions provide a mechanism by which GAGs exert their
control over critical biological processes. However, unlike the binary
on/off concept generally applied to the understanding of protein
activity regulation (e.g., receptor binding and activation), GAGs
exhibit a gradation of control through the diverse nature of their
disaccharide sequence, chemical organization, and chain length. The
inherent heterogeneity of GAG chains is a product of nontemplate-
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based biosynthesis [5]. The ability to characterize this complexity
remains a challenge with the current analytical methods, and as a
consequence, progress in deciphering GAG structure-function
relationships has been hindered.
The most structurally complex member of the GAG family is
heparan sulfate, having an information-dense chain carrying
potentially 48 different disaccharide structures segregated into
chemical blocks of highly sulfated and largely unsulfated domains
[1,8,9]. Heparan sulfate is a major physiological player at the cell-
extracellular matrix interface where it has been shown to interact
with and mediate the activity of a number of proteins. Many HS-
protein interactions appear to be less dependent on the specific
disaccharide sequence and more dependent on the domain
organization of the HS chain [3,5,9,12]. Because the analytical
capability to detect domain organization is currently limited, new
methods that can provide insight into HS chain organization will
be extremely useful to researchers in the field.
Several early attempts with mathematical modeling [51] and
computer simulation [52–55] were focused on the structure of
heparin. These methods were used in conjunction with cleavage
experiments to test alternative hypotheses concerning the action
pattern of heparin lyase I and the arrangement of specific
oligosaccharides within the heparin chain. Although the method-
ology was later applied to hyaluronic acid and the action of
hyaluronate lyase [56], the extension of these techniques to the
more complex structure of HS was not implemented.
The computational approach described in this study offers a
unique way to probe the organizational structure of HS chains.
Using minimal experimental data from disaccharide analysis and
selective heparin lyase digestion, the computational routines can
generate chains according to rules of HS biosynthesis and lyase
specificity and then transform them into strings of user-defined
domains for pattern analysis. As demonstrated with HS chain
populations from two different cell culture sources, the model has
the ability to predict significant differences in overall domain
organization properties as well as in the density and distribution of
specific functional motifs. HS activity measurements revealed that
Figure 6. Specific motif for inhibition of elastolysis predicted
for fibroblast HS and epithelial HS. (A) Chemical structure of the
disaccharide pair that defines the cluster domain. Disaccharides
excluded from the cluster domain belong to the connector domain.
(B) Schematic diagram of HS chains showing domain organization with
specific motif for inhibition of elastolysis. Yellow blocks are cluster
domains; blue blocks are connector domains; dark blue blocks are
connector domains that meet the size requirement for effective elastase
inhibition. Chain lengths are 250 disaccharides. Minimum block length
is 1 disaccharide. (C) Size distribution of connector domains in HS
chains. N=250 disaccharides and M=100 chains. Crosshatched bars
indicate lengths of connector domains (2–20 disaccharides) for effective
elastase inhibition. Although the distribution is shown for connector
domains up to 100 disaccharides in length, longer domains are present
in both sets of HS chains. For fibroblast HS, connector domains extend
to 226 disaccharides with an average size of 5265 disaccharides
(average695% confidence limits). For epithelial HS, connector domains
extend to 184 disaccharides with an average size of 3663 disaccharides.
(D) Inhibition of elastolysis by GAG preparations. Relative rate = (elastin
digestion with inhibitor)/(elastin digestion without inhibitor). Bar height
equals the average of duplicate readings; error bar shows the
propagation-of-error estimate using standard errors. Control = no
inhibitor; Hep = commercial heparin (17–19 kDa); HS = commercial
heparan sulfate (8–10 kDa); Fibro HS = HS preparation from rat
pulmonary fibroblasts; Epi HS = HS preparation from rat pulmonary
epithelial cells. Reaction conditions: [Inhibitor] = 5.0 mg/mL; [HNE
(human neutrophil elastase)] = 120 nM; [Elastin] = 0.93 mg/mL; buffer
= Dulbecco’s phosphate-buffered saline without calcium and magne-
sium salts; temperature = 37uC; time = 4 hours; volume =1.073 mL.
doi:10.1371/journal.pone.0009389.g006
Computational Analysis of GAGs
PLoS ONE | www.plosone.org 11 February 2010 | Volume 5 | Issue 2 | e9389
these structural differences are related to functional differences in
HS-protein interactions. Hence these tools can be used in
conjunction with experimental measurement to investigate the
relationship between proposed structural requirements and
functional activities in HS.
The existence of a causal relationship between cell-surface HS
structure and cell behavior is supported by various studies. HS
chains from different cell types have been reported to have
consistent structural variations that result in distinct biological
functions [57–59]. For example, experimental measurements of
HS chains purified from the surfaces of mouse mammary gland
epithelial cells and embryonic fibroblasts showed differences in
structure (chain length and disaccharide composition of highly
sulfated domains) as well as binding to type I collagen [58]. The
current investigation is consistent with these earlier studies and
provides additional evidence for cell type-specific differences in HS
structure that have direct functional consequences. In this case,
however, these differences include not only analytical measure-
ments of disaccharide compositions for the chain and lyase-specific
domains but also computer-predicted patterns of overall domain
structure and specific functional motifs. On both a large and small
scale, the differences in HS structure appear to contribute to the
ability of different cell types to appropriately respond to molecular
signals in their particular microenvironment.
For the pulmonary fibroblasts and epithelial cells used in this
study, the cellular microenvironments are quite different. The
epithelial cells form a tight barrier of cell-to-cell contacts in a layer
(epithelium) that lines the pulmonary airspace. There is minimum
extracellular matrix around the epithelial cells except at the basal
surface where they juxtapose a thin layer called the basal lamina.
By contrast, the fibroblasts exist in isolation from one another in a
generous layer of extracellular matrix and fibrous polymers that
forms the connective tissue support of the epithelium [60]. As a
result of these unique microenvironments, distinctly different
biological responses are required from the resident cells. Because
the epithelial cells are positioned at the forefront of the airway,
their major function is to defend the lung by actions that include
providing a barrier and clearance mechanism for environmental
agents, modulating the inflammatory response, and regulating
cellular activities in response to injury [61]. The fibroblasts,
however, embedded within the interior of the tissue, assiduously
maintain the integrity of the structure by producing the
components of the extracellular matrix (e.g., collagens, elastin,
fibronectin, and proteoglycans) and when required, migrate to
sites of injury to proliferate and produce large amounts of matrix
[60,62].
Considering the diverse biological functions of pulmonary
fibroblasts and epithelial cells, it is not surprising that a different
structural organization would be predicted for the cell-surface HS
chains of these two cell types. Since the epithelial cells are the first
line of defense against injury caused by excessive release of elastase
by neutrophils, they may have need for a more potent HS
structure for binding and inhibiting this protease as a means to
restrict its action to sites of injury or infection. Their HS structure
may be more condensed (higher frequency of highly sulfated
domains) because of the shorter range of operation among the
closely packed epithelial cells. On the other hand, the fibroblasts
exist as a sparse population in the extracellular matrix where
distances are considerable. An HS structure that is more spread
out (lower frequency of highly sulfated domains) may be more
practical for these longer range interactions. Since the extracellular
matrix also contains a convenient source of HS proteoglycans,
excessive elastase activity within the matrix may be more readily
addressed by extracellular HS chains, either as intact proteogly-
cans or as fragments released by injury. Consequently, the HS
chains on the surface of the fibroblasts may have less need to be as
effective in inhibiting elastase as their counterparts on the
epithelial cells.
The ability to read and interpret the patterns of HS chains will
have far-reaching implications for understanding the biological
function of these complex glycans. The analysis of these patterns
can be handled in many different ways, and as illustrated with the
computer-generated chains of this study, the results can reveal
varied aspects of the same chain depending on the chosen method.
If the emphasis is placed on the macro organization of the chain,
the calculation of the average domain size and the Fourier power
spectrum are reasonable techniques for characterizing the overall
domain pattern for a group of chains. However, the model
generates unique chains, and although the general pattern gives a
sense of the properties and potential activity of the population of
chains as a whole, there is no single chain pattern that exactly
matches the average chain pattern (compare Figures 3B and 4D).
The existence of individual chains with unique sequences provides
an opportunity to evaluate the relative density of rare patterns
within the population of chains or to search for distinct local
patterns within each chain. Thus, differences in the biological
activities of various HS chain populations, including HS isolated
from diseased and nondiseased tissues, can be correlated to
differences in either the overall domain organization or the
presence of specific structural motifs within the population.
Even though sequence analysis was not the impetus behind
developing this computational model, it appears that it may be a
powerful byproduct of the overall process. In fact, a system that
can integrate the computational model with the current analytical
sequencing technology may have the potential to actually
‘‘sequence’’ entire biologically active HS chains. The strategy
behind such a system would be to use a sequencing technique to
explicitly define the major oligosaccharides (ten or less sugars)
from the partial degradation of the chain by one or more schemes.
These fully sequenced chain fragments would then be input as a
set of constraints for the model. As each chain is generated by the
program, the simulated sequence would be searched for matches
with the real fragments. Chains would be ranked as a function of
the number of matches, and the top-scoring chain or chains would
represent the best solution for the sequence of the real chain.
Although future work will focus on refining the computational
model, there are two aspects of its basic design that should be
emphasized. On a practical level, the first and perhaps more
important factor is that the model does not require extraordinary
means to achieve results. The experimental data are fairly
straightforward to obtain by standard laboratory methods, and
the computer program is executable on a personal computer. The
second and less obvious factor is that the model has a modular
structure. This allows for great flexibility in modifying specific
parts of the model, such as the rules for chain position or lyase
digestion, or in adding new parts, such as the generation of chains
from a normal distribution of lengths. Moreover, because of this
modular structure, the model is rather broad in application and
can be tailored to other glycosaminoglycans or enzymes, such as
chondroitin sulfate and associated chondroitin lyases.
While basic information is sufficient for operation of the model,
it is apparent that the more complete these data are, the more
closely the predicted chains will represent the real chains. For
example, instead of using estimates of the glucuronic acid/
iduronic acid ratio from the literature, improved values can be
determined by comparing data from chemical and enzymatic
degradations of the actual sample [36]. As another example, if the
molecular weight distribution of the sample is obtained, an
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average chain length or a distribution of chain lengths can be
defined, replacing the generation of chains over an arbitrary range
of lengths with a more realistic representation of the sample [63].
An overriding issue for any simulation is how well the
predictions agree with the real system. Confidence in the predicted
results can only be established through model validation, and
future work will focus on addressing this critical element [64].
Although there is insufficient knowledge on the domain organi-
zation of HS chains for direct comparison, an indirect method can
be used to apply the model to experimental data from HPLC
profiling that identify both the disaccharide and oligosaccharide
products after selective heparin lyase digestion. The presence of
substantial disagreement may suggest refinements to the internal
rules for chain synthesis or enzyme degradation that will bring the
model predictions closer to reality. A high level of agreement
between the predicted results and the data will establish credibility
for the model.
The true value of this model rests on whether it answers the
question that prompted its development; namely, can knowing the
domain organization of HS chains increase understanding of HS
function. For example, activities of HS samples such as protein
binding, enzyme inhibition, and cell regulation can be measured
and related to domain structure. Toward this end, evaluation of
the elastase inhibitory potential of the HS samples used in this
study has indicated differences that might relate to altered domain
organization. These differences may also have physiological
implications regarding the particular role of these HS populations
in their cell type of origin. For instance, the ability of HS from lung
epithelial cells to inhibit elastase activity may contribute to the
normal control of tissue damage at sites of inflammation where
neutrophil elastase has been shown to be involved. As the model is
refined and applied in conjunction with additional functional
measurements with a wide range of HS samples, there are
reasonable expectations that new mechanisms for the activity of
HS and proteoglycans will be revealed.
The conceptual framework for an innovative computational
approach to predict patterns of domain organization within a
population of HS chains is presented. This model will give
investigators the ability to consider high-level chain organization
in understanding HS-protein interactions. The approach de-
scribed here will likely provide the basis for the development of a
new class of tools to probe for structure-function relationships in
glycosaminoglycans that may ultimately be used to design selective
drugs that target GAG-protein interactions associated with disease.
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